Latest luspatercept readout a second win for Acceleron, Celgene

Acceleron Pharma Inc. (NASDAQ:XLRN) climbed $1.36 to $48.76 Tuesday after it and partner Celgene Corp. (NASDAQ:CELG) said luspatercept (ACE-536) met the primary endpoint in the Phase III BELIEVE study to treat beta-thalassemia. The companies are planning regulatory submissions for the candidate in the

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE